A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY‐HF study-Reference-Cited by-同舟云学术

A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY‐HF study

Published:2021-10-12 Issue:12 Volume:23 Page:2073-2082
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Halle Martin¹²,Schöbel Christoph³,Winzer Ephraim B.⁴,Bernhardt Peter⁵,Mueller Stephan¹²,Sieder Christian⁶,Lecker Laura S.M.⁶

Affiliation:

1. Department of Prevention and Sports Medicine University Hospital Klinikum rechts der Isar, Technical University of Munich Munich Germany

2. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany

3. Department of Cardiology and Angiology, Campus Mitte Charité‐Universitätsmedizin Berlin Berlin Germany

4. Heart Centre Dresden University Hospital Technische Universität Dresden Dresden Germany

5. Heart Clinic Ulm Ulm Germany

6. Novartis Pharmaceuticals Nürnberg Germany

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2355

Reference31 articles.

1. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years

2. Modest Increase in Peak VO 2 Is Related to Better Clinical Outcomes in Chronic Heart Failure Patients

3. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

4. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM);European Journal of Heart Failure;2024-05-27

2. Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials;European Journal of Clinical Pharmacology;2024-04-10

3. Myocardial Recovery in the Systemic Context: A Philosophic Shift for the Heart Failure Subspecialty to Optimize Patient Care;Methodist DeBakey Cardiovascular Journal;2024

4. Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials;Hospital Pharmacy;2023-12-06

5. Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials;Cureus;2023-11-11